UB Paderborn / Katalog / Suche / in CDI

1 – 9 von 9

Sortiert nach

Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

Frontiers in immunology, 2024, Vol.15, p.1352615-1352615

2024

Volltextzugriff (PDF)

Use of next-gen sequencing in an integrated companion diagnostics workflow

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e23273-e23273

2016

Volltextzugriff (PDF)

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer

Anticancer research, 2018-04, Vol.38 (4), p.2261

2018

Volltextzugriff (PDF)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

Oncotarget, 2015-02, Vol.6 (4), p.1954-1966

2015

Volltextzugriff (PDF)

Characterizing heterogeneic tumor profiles with an integrated companion diagnostics approach

Integrative cancer science and therapeutics, 2016, Vol.3 (4), p.500-503

2016

Volltextzugriff (PDF)

86 Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A94-A94

2021

Volltextzugriff (PDF)

Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.382-382

2017

Volltextzugriff (PDF)

OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S260-S261

2017

Volltextzugriff (PDF)

1 – 9 von 9

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7)
Mit Volltextzugriff
(9)

Publikationsform

Artikel
(9)

Sprache

Englisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(4)
Science & Technology
(4)
Humans
(3)
Immunohistochemistry
(3)
Oncology
(3)
Aged
(2)
Female
(2)
Lung Cancer
(2)
Lung Neoplasms - Pathology
(2)
Male
(2)
Medical Prognosis
(2)
Middle Aged
(2)
Tumors
(2)
Aged, 80 And Over
(1)
Amuvatinib
(1)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(1)
Antineoplastic Agents - Therapeutic Use
(1)
Benzodiazepinones - Therapeutic Use
(1)
Biomarkers, Tumor - Genetics
(1)
Biomarkers, Tumor - Metabolism
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(2)
Anticancer Research
(1)
Frontiers In Immunology
(1)
Integrative Cancer Science And Therapeutics
(1)
Journal For Immunotherapy Of Cancer
(1)
Journal Of Thoracic Oncology
(1)
Oncotarget
(1)
The Lancet Oncology
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

Use of next-gen sequencing in an integrated companion diagnostics workflow

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

Characterizing heterogeneic tumor profiles with an integrated companion diagnostics approach

86 Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies

Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC)

OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

Suchergebnisse filtern